HelloFresh Q3 Revenue Down 11.3% YoY

HelloFresh reported Q3 2026 revenue of 1.4B euros, down 11.3% YoY. Meal Kits and RTE segments declined 13.1% and 11.1% respectively. AEBITDA rose 26.3% to 50.9M euros. The company expects 2026 revenue to fall 9-11% and AEBITDA to be 350-370M euros. Shares closed at 2.99 euros on Xetra.

Original reporting
Published Nov 5, 2026, 6:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 6:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HelloFresh Q3 Revenue Down 11.3% YoY — source image
Decision brief

The 30-second read

$HFGBearishMed
01

Why it matters

The revenue decline may trigger short‑term sell‑offs, but AEBITDA growth could support a longer‑term view.

02

Market read

Earnings miss could depress the stock and influence the European consumer discretionary sector.

03

What to watch

Potential cost‑saving measures and upcoming product innovations are not reflected in the current numbers.

Relevance 8/10Novelty 8/10Timing: post‑market release

Background

HelloFresh is a leading global meal‑kit and ready‑to‑eat provider, listed on Xetra (ticker HFG). The Q3 2026 results were released on 5 Nov 2026.

Company-level read

Ticker impact

$HFGBearishMedium confidence
Context

HelloFresh reported Q3 2026 constant‑currency revenue of €1.4 bn, down 11.3% YoY, with Meal Kits revenue down 13.1% and RTE down 11.1%; AEBITDA rose 26.3% to €50.9 mn and guidance shows 2026 revenue decline of 9‑11%.

Expected impact

downward pressure as investors price in weaker top‑line growth

Evidence & confidence

The sizable revenue decline exceeds typical expectations and may trigger sell‑offs, while modest AEBITDA improvement may not offset the top‑line weakness.

Market effects

Highlights pressure on the broader meal‑kit and ready‑to‑eat food sector, potentially affecting peers.

European consumer discretionary sentiment may soften.

Limited to food‑service segment; minimal global macro impact.

Counterpoint

AEBITDA growth and higher average order value could signal operational resilience, offering a buying opportunity on a dip.

Key entities

  • HelloFresh SE

    Meal‑kit and ready‑to‑eat food provider.

Related articles

$HFGMed

HelloFresh cuts 2026 outlook as marketing cuts hit customer growth

HelloFresh SE (HFGG) reduced its 2026 revenue and profit outlook, citing deeper marketing cuts that hurt customer growth. It now expects a 9-11% revenue decline, below its prior forecast and analyst consensus. Q3 revenue is projected to fall 11-12%, and adjusted EBITDA is expected at €45-55 million, also below consensus. The company blames the weaker outlook on larger-than-planned Q3 marketing reductions.

$TMHighAI 9/10

Toyota hikes profit forecasts on strong demand, weak yen

Toyota raised its full-year profit forecasts to 3.57 trillion yen ($22.6 billion) due to strong hybrid vehicle demand and a weak yen, despite competition. Q2 profit fell 18.5% year-on-year, but revenue rose 8.6%. Full-year revenue is expected to grow 5.6% to 53.5 trillion yen. The company cited production recovery and supply optimization efforts.

$TASKHighAI 8/10

TaskUs Q3 Earnings Call Highlights

TaskUs (TASK) raised its 2026 revenue outlook to $1.249-$1.251B (5.6% YoY growth) and adjusted free cash flow forecast to $115-$125M. Q4 revenue is expected at $319-$321M. The company plans increased AI investments in 2027, which may constrain near-term margins. TaskUs secured new AI-related contracts and expects cash flow from operations to rise.

$SITMHigh

SiTime Q3 Earnings Call Highlights

SiTime reported Q3 non-GAAP gross margin of 70.7%, up 11.9% YoY, driven by higher-value products. Revenue growth improved manufacturing absorption. Non-GAAP net income rose over fivefold to $130.3M, with EPS of $4.01. The company expects Q4 gross margin around 70% and EPS of ~$4.76. Supply constraints for TPD wafers are expected to persist through 2027. SiTime plans a 2-for-1 stock split, effective Dec. 7, 2026.

$RVMDMed

What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

Revolution Medicines (RVMD) reported Q3 earnings, highlighting RASONQUE's reimbursement progress, regulatory updates, and pipeline advancements. RASONQUE is included in NCCN guidelines for pancreatic cancer. The company expects European and potential Japanese launches. Q3 revenue included initial stocking, with R&D expenses rising to $417.1M. RVMD ended the quarter with $3.7B in cash. The company reiterated 2026 operating expense guidance and anticipates higher 2027 expenses.